blenoxane pws 15unit powder for solution
bristol labs division of bristol-myers squibb - bleomycin sulfate - powder for solution - 15unit - bleomycin sulfate 15unit - antineoplastic agents
bleomycin for injection powder for solution
fresenius kabi canada ltd - bleomycin (bleomycin sulfate) - powder for solution - 15unit - bleomycin (bleomycin sulfate) 15unit - antineoplastic agents
bleomycin for injection usp powder for solution
sandoz canada incorporated - bleomycin (bleomycin sulfate) - powder for solution - 15unit - bleomycin (bleomycin sulfate) 15unit - antineoplastic agents
deferasirox synthon hispania 90mg film-coated tablets
synthon hispania, s.l. calle castello 1, 08830 sant boi de llobregat, barcelona, spain - deferasirox - film-coated tablet - deferasirox 90 mg - all other therapeutic products
deferasirox synthon hispania 360mg film-coated tablets
synthon hispania, s.l. calle castello 1, 08830 sant boi de llobregat, barcelona, spain - deferasirox - film-coated tablet - deferasirox 360 mg - all other therapeutic products
deferasirox synthon hispania 180mg film-coated tablets
synthon hispania, s.l. calle castello 1, 08830 sant boi de llobregat, barcelona, spain - deferasirox - film-coated tablet - deferasirox 180 mg - all other therapeutic products
caeseva 800mg film coated tablet
duopharma (m) sdn. bhd. - sevelamer carbonate -
dasatinib taro 100 mg
taro international ltd, israel - dasatinib - film coated tablets - dasatinib 100 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with: * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.
dasatinib taro 140 mg
taro international ltd, israel - dasatinib - film coated tablets - dasatinib 140 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with: * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.
dasatinib taro 20 mg
taro international ltd, israel - dasatinib - film coated tablets - dasatinib 20 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with: * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.